Immunovant, Inc. (IMVT)

Immunovant Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net Income	-323.01	-259.34	-210.96	-156.73	-107.43	-66.39
Depreciation & Amortization	0.29	0.23	0.19	0.13	0.07	0.02
Other Amortization	-	-	-	-	-	1.63
Loss (Gain) From Sale of Assets	-	-	-	-	-	0.01
Stock-Based Compensation	46.05	41.12	32.3	34.24	18.82	6.96
Other Operating Activities	0.64	1.13	1.13	1.11	0.65	-0.4
Change in Accounts Receivable	-0.53	-4.58	11.76	-11.63	-0.6	-
Change in Accounts Payable	12.94	5.78	-17.12	16.25	1.25	0.97
Change in Income Taxes	0.02	0.02	0.46	-0.09	-0.51	0.01
Change in Other Net Operating Assets	-8.04	1.41	-5.95	10.61	4.42	3.83
Operating Cash Flow	-271.64	-214.23	-188.19	-106.11	-83.33	-53.36
Capital Expenditures	-0.66	-0.36	-0.2	-0.25	-0.21	-0.03
Investing Cash Flow	-0.66	-0.36	-0.2	-0.25	-0.21	-0.03
Short-Term Debt Issued	-	-	-	-	-	42.91
Total Debt Issued	-	-	-	-	-	42.91
Short-Term Debt Repaid	-	-	-	-	-3.19	-5
Total Debt Repaid	-	-	-	-	-3.19	-5
Net Debt Issued (Repaid)	-	-	-	-	-3.19	37.91
Issuance of Common Stock	478.82	478.44	71.16	200.13	387.54	1.16
Other Financing Activities	-6.01	-6.01	-0.27	-	-1.24	107.91
Financing Cash Flow	472.81	472.43	70.89	200.13	383.11	146.97
Foreign Exchange Rate Adjustments	2.51	0.99	0.22	-0.09	-	-
Net Cash Flow	203.01	258.83	-117.29	93.67	299.58	93.59
Free Cash Flow	-272.3	-214.59	-188.39	-106.37	-83.54	-53.39
Free Cash Flow Per Share	-1.87	-1.55	-1.53	-0.97	-0.95	-1.24
Cash Income Tax Paid	0.81	0.51	-	-	0.17	0.06
Levered Free Cash Flow	-160.83	-124.15	-107.82	-47.88	-43.79	-28.94
Unlevered Free Cash Flow	-160.83	-124.15	-107.82	-47.88	-43.79	-28.55
Change in Net Working Capital	-13.78	-3.74	9.94	-15.53	-5.11	-2.73

Source: S&P Capital IQ. Standard template. Financial Sources.